Literature DB >> 11283137

Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.

A Morgner1, S Miehlke, W Fischbach, W Schmitt, H Müller-Hermelink, A Greiner, C Thiede, J Schetelig, A Neubauer, M Stolte, G Ehninger, E Bayerdörffer.   

Abstract

PURPOSE: Treatment of low-grade gastric mucosa-associated lymphoid tissue lymphoma by eradication of Helicobacter pylori is reported to result in complete lymphoma remission in approximately 75% of cases. The effect that cure of the infection has on the course of a primary high-grade gastric lymphoma is largely uncertain. The aim of this study was to report the effect of cure of H pylori infection exerted in patients with high-grade B-cell gastric lymphoma. PATIENTS AND METHODS: Eight patients (4 males and 4 females; age range, 26 to 85 years) with H pylori infection and high-grade lymphoma received eradication therapy before planned treatment. The effect of H pylori eradication on the course of high-grade lymphoma was assessed by analysis of surgical specimens (n = 2) or endoscopic biopsies (n = 6).
RESULTS: H pylori eradication was successful in all patients and led to complete remission of the lymphoma in seven patients. One patient has experienced partial remission. Two patients were referred to surgery, one of whom (stage II(1E)) had lymph node involvement, and the histologic work-up of the resected stomach revealed residual infiltrates of a low-grade lymphoma, which prompted consolidation chemotherapy. In one patient (initially stage I(1E)), abdominal lymphoma developed 6 months after eradication therapy, which regressed completely after chemotherapy. In four patients, no further treatment was given. Six patients continue in complete remission (range, 6 to 66 months).
CONCLUSION: Primary high-grade B-cell gastric lymphoma in stages I(E) through II(E1) associated with H pylori may regress completely after successful cure of the infection. Prospective trials are needed to investigate this treatment in larger numbers of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283137     DOI: 10.1200/JCO.2001.19.7.2041

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

1.  Distinction between "high grade MALT" and diffuse large B cell lymphoma. Mucosa associated lymphoid tissue.

Authors:  S Ely
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 2.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 3.  Helicobacter pylori eradication in gastric diffuse large B cell lymphoma.

Authors:  Semra Paydas
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 4.  Long-term follow-up of gastric MALT lymphoma after H. pylori eradication.

Authors:  A Morgner; C Thiede; E Bayerdörffer; B Alpen; T Wündisch; A Neubauer; M Stolte
Journal:  Curr Gastroenterol Rep       Date:  2001-12

5.  Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins.

Authors:  Jie Yan; Shao-Hui Liang; Ya-Fei Mao; Li-Wei Li; Shu-Ping Li
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

7.  Construction of hpaA gene from a clinical isolate of Helicobacter pylori and identification of fusion protein.

Authors:  Ya-Fei Mao; Jie Yan; Li-Wei Li; Shu-Ping Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

8.  Construction of prokaryotic expression system of ureB gene from a clinical Helicobacter pylori strain and identification of the recombinant protein immunity.

Authors:  Ya-Fei Mao; Jie Yan
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

9.  Construction of a prokaryotic expression system of vacA gene and detection of vacA gene, VacA protein in Helicobacter pylori isolates and ant-VacA antibody in patients' sera.

Authors:  Jie Yan; Ya-Fei Mao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

Review 10.  De-escalating therapy in gastric aggressive lymphoma.

Authors:  Rosanna Cuccurullo; Silvia Govi; Andrés J M Ferreri
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.